Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.
Identifieur interne : 001C06 ( PubMed/Corpus ); précédent : 001C05; suivant : 001C07Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.
Auteurs : Sarah Lilian Pett ; Janaki Amin ; Andrejz Horban ; Jaime Andrade-Villanueva ; Marcelo Losso ; Norma Porteiro ; Juan Sierra Madero ; Waldo Belloso ; Elise Tu ; David Silk ; Anthony Kelleher ; Richard Harrigan ; Andrew Clark ; Wataru Sugiura ; Marcelo Wolff ; John Gill ; Jose Gatell ; Martin Fisher ; Amanda Clarke ; Kiat Ruxrungtham ; Thierry Prazuck ; Rolf Kaiser ; Ian Woolley ; Juan Alberto Arnaiz ; David Cooper ; Jürgen K. Rockstroh ; Patrick Mallon ; Sean EmerySource :
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [ 1537-6591 ] ; 2016.
English descriptors
- KwdEn :
- Adult, Comorbidity, Cyclohexanes (therapeutic use), Female, HIV Fusion Inhibitors (therapeutic use), HIV Infections (drug therapy), HIV Infections (epidemiology), HIV Infections (virology), HIV Protease Inhibitors (therapeutic use), Humans, Male, Middle Aged, Reverse Transcriptase Inhibitors (therapeutic use), Ritonavir (therapeutic use), Treatment Outcome, Triazoles (therapeutic use), Viral Load, Virus Replication.
- MESH :
- chemical , therapeutic use : Cyclohexanes, HIV Fusion Inhibitors, HIV Protease Inhibitors, Reverse Transcriptase Inhibitors, Ritonavir, Triazoles.
- drug therapy : HIV Infections.
- epidemiology : HIV Infections.
- virology : HIV Infections.
- Adult, Comorbidity, Female, Humans, Male, Middle Aged, Treatment Outcome, Viral Load, Virus Replication.
Abstract
Alternative combination antiretroviral therapies in virologically suppressed human immunodeficiency virus (HIV)-infected patients experiencing side effects and/or at ongoing risk of important comorbidities from current therapy are needed. Maraviroc (MVC), a chemokine receptor 5 antagonist, is a potential alternative component of therapy in those with R5-tropic virus.
DOI: 10.1093/cid/ciw207
PubMed: 27048747
Links to Exploration step
pubmed:27048747Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.</title><author><name sortKey="Pett, Sarah Lilian" sort="Pett, Sarah Lilian" uniqKey="Pett S" first="Sarah Lilian" last="Pett">Sarah Lilian Pett</name><affiliation><nlm:affiliation>The Kirby Institute, University of New South Wales, Sydney, Australia Medical Research Council Clinical Trials Unit, Institute of Clinical Trials and Methodology Clinical Research Group, Infection and Population Health, University College London, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Amin, Janaki" sort="Amin, Janaki" uniqKey="Amin J" first="Janaki" last="Amin">Janaki Amin</name><affiliation><nlm:affiliation>The Kirby Institute, University of New South Wales, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Horban, Andrejz" sort="Horban, Andrejz" uniqKey="Horban A" first="Andrejz" last="Horban">Andrejz Horban</name><affiliation><nlm:affiliation>Wojewodzki Szpital Zakazny Centrum Diagnostyki i Terapii AIDS, Warsaw, Poland.</nlm:affiliation></affiliation></author><author><name sortKey="Andrade Villanueva, Jaime" sort="Andrade Villanueva, Jaime" uniqKey="Andrade Villanueva J" first="Jaime" last="Andrade-Villanueva">Jaime Andrade-Villanueva</name><affiliation><nlm:affiliation>Hospital Civil de Guadalajara "Fray Antonio Alcalde," Jalisco, Mexico.</nlm:affiliation></affiliation></author><author><name sortKey="Losso, Marcelo" sort="Losso, Marcelo" uniqKey="Losso M" first="Marcelo" last="Losso">Marcelo Losso</name><affiliation><nlm:affiliation>Hospital General de Agudos J M Ramos Mejia Fundación IBIS Coordinacion de Investigacion Clinica Academica en Latinoamerica.</nlm:affiliation></affiliation></author><author><name sortKey="Porteiro, Norma" sort="Porteiro, Norma" uniqKey="Porteiro N" first="Norma" last="Porteiro">Norma Porteiro</name><affiliation><nlm:affiliation>Fundación Infectologia de Atencion Ambulatoria, Buenos Aires, Argentina.</nlm:affiliation></affiliation></author><author><name sortKey="Sierra Madero, Juan" sort="Sierra Madero, Juan" uniqKey="Sierra Madero J" first="Juan" last="Sierra Madero">Juan Sierra Madero</name><affiliation><nlm:affiliation>Instituto Nacional de Ciencias Medicas y Nutriciòn Salvador Zubiran, Tlalpan, Mexico.</nlm:affiliation></affiliation></author><author><name sortKey="Belloso, Waldo" sort="Belloso, Waldo" uniqKey="Belloso W" first="Waldo" last="Belloso">Waldo Belloso</name><affiliation><nlm:affiliation>Fundación IBIS Coordinacion de Investigacion Clinica Academica en Latinoamerica Hospital Italiano de Buenos Aires, Argentina.</nlm:affiliation></affiliation></author><author><name sortKey="Tu, Elise" sort="Tu, Elise" uniqKey="Tu E" first="Elise" last="Tu">Elise Tu</name><affiliation><nlm:affiliation>The Kirby Institute, University of New South Wales, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Silk, David" sort="Silk, David" uniqKey="Silk D" first="David" last="Silk">David Silk</name><affiliation><nlm:affiliation>The Kirby Institute, University of New South Wales, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Kelleher, Anthony" sort="Kelleher, Anthony" uniqKey="Kelleher A" first="Anthony" last="Kelleher">Anthony Kelleher</name><affiliation><nlm:affiliation>The Kirby Institute, University of New South Wales, Sydney, Australia St Vincent's Hospital, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Harrigan, Richard" sort="Harrigan, Richard" uniqKey="Harrigan R" first="Richard" last="Harrigan">Richard Harrigan</name><affiliation><nlm:affiliation>British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Clark, Andrew" sort="Clark, Andrew" uniqKey="Clark A" first="Andrew" last="Clark">Andrew Clark</name><affiliation><nlm:affiliation>ViiV Healthcare Ltd, London, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Sugiura, Wataru" sort="Sugiura, Wataru" uniqKey="Sugiura W" first="Wataru" last="Sugiura">Wataru Sugiura</name><affiliation><nlm:affiliation>Nagoya Medical Centre, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Wolff, Marcelo" sort="Wolff, Marcelo" uniqKey="Wolff M" first="Marcelo" last="Wolff">Marcelo Wolff</name><affiliation><nlm:affiliation>Fundacion Arriaran, Santiago, Chile.</nlm:affiliation></affiliation></author><author><name sortKey="Gill, John" sort="Gill, John" uniqKey="Gill J" first="John" last="Gill">John Gill</name><affiliation><nlm:affiliation>Southern Alberta Clinic, Calgary, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Gatell, Jose" sort="Gatell, Jose" uniqKey="Gatell J" first="Jose" last="Gatell">Jose Gatell</name><affiliation><nlm:affiliation>Hospital Clinic de Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Fisher, Martin" sort="Fisher, Martin" uniqKey="Fisher M" first="Martin" last="Fisher">Martin Fisher</name><affiliation><nlm:affiliation>Brighton and Sussex University Hospitals National Health Service Trust, Brighton, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Clarke, Amanda" sort="Clarke, Amanda" uniqKey="Clarke A" first="Amanda" last="Clarke">Amanda Clarke</name><affiliation><nlm:affiliation>Brighton and Sussex University Hospitals National Health Service Trust, Brighton, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Ruxrungtham, Kiat" sort="Ruxrungtham, Kiat" uniqKey="Ruxrungtham K" first="Kiat" last="Ruxrungtham">Kiat Ruxrungtham</name><affiliation><nlm:affiliation>HIV Netherlands, Australia, Thailand Research Collaboration, Bangkok.</nlm:affiliation></affiliation></author><author><name sortKey="Prazuck, Thierry" sort="Prazuck, Thierry" uniqKey="Prazuck T" first="Thierry" last="Prazuck">Thierry Prazuck</name><affiliation><nlm:affiliation>Orleans Hospital (Centre Hospitalier Regional D'Orleans Orleans La Source), France.</nlm:affiliation></affiliation></author><author><name sortKey="Kaiser, Rolf" sort="Kaiser, Rolf" uniqKey="Kaiser R" first="Rolf" last="Kaiser">Rolf Kaiser</name><affiliation><nlm:affiliation>Institut für Virologie, Cologne, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Woolley, Ian" sort="Woolley, Ian" uniqKey="Woolley I" first="Ian" last="Woolley">Ian Woolley</name><affiliation><nlm:affiliation>Monash Medical Centre, Melbourne, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Arnaiz, Juan Alberto" sort="Arnaiz, Juan Alberto" uniqKey="Arnaiz J" first="Juan Alberto" last="Arnaiz">Juan Alberto Arnaiz</name><affiliation><nlm:affiliation>Fundacion Clinic Spain Clinical Trials Unit, Barcelona.</nlm:affiliation></affiliation></author><author><name sortKey="Cooper, David" sort="Cooper, David" uniqKey="Cooper D" first="David" last="Cooper">David Cooper</name><affiliation><nlm:affiliation>The Kirby Institute, University of New South Wales, Sydney, Australia St Vincent's Hospital, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Rockstroh, Jurgen K" sort="Rockstroh, Jurgen K" uniqKey="Rockstroh J" first="Jürgen K" last="Rockstroh">Jürgen K. Rockstroh</name><affiliation><nlm:affiliation>Department of Medicine I, University Hospital Bonn, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Mallon, Patrick" sort="Mallon, Patrick" uniqKey="Mallon P" first="Patrick" last="Mallon">Patrick Mallon</name><affiliation><nlm:affiliation>Mater Misericordiae University Hospital, Dublin, Ireland.</nlm:affiliation></affiliation></author><author><name sortKey="Emery, Sean" sort="Emery, Sean" uniqKey="Emery S" first="Sean" last="Emery">Sean Emery</name><affiliation><nlm:affiliation>The Kirby Institute, University of New South Wales, Sydney, Australia.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27048747</idno><idno type="pmid">27048747</idno><idno type="doi">10.1093/cid/ciw207</idno><idno type="wicri:Area/PubMed/Corpus">001C06</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001C06</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.</title><author><name sortKey="Pett, Sarah Lilian" sort="Pett, Sarah Lilian" uniqKey="Pett S" first="Sarah Lilian" last="Pett">Sarah Lilian Pett</name><affiliation><nlm:affiliation>The Kirby Institute, University of New South Wales, Sydney, Australia Medical Research Council Clinical Trials Unit, Institute of Clinical Trials and Methodology Clinical Research Group, Infection and Population Health, University College London, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Amin, Janaki" sort="Amin, Janaki" uniqKey="Amin J" first="Janaki" last="Amin">Janaki Amin</name><affiliation><nlm:affiliation>The Kirby Institute, University of New South Wales, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Horban, Andrejz" sort="Horban, Andrejz" uniqKey="Horban A" first="Andrejz" last="Horban">Andrejz Horban</name><affiliation><nlm:affiliation>Wojewodzki Szpital Zakazny Centrum Diagnostyki i Terapii AIDS, Warsaw, Poland.</nlm:affiliation></affiliation></author><author><name sortKey="Andrade Villanueva, Jaime" sort="Andrade Villanueva, Jaime" uniqKey="Andrade Villanueva J" first="Jaime" last="Andrade-Villanueva">Jaime Andrade-Villanueva</name><affiliation><nlm:affiliation>Hospital Civil de Guadalajara "Fray Antonio Alcalde," Jalisco, Mexico.</nlm:affiliation></affiliation></author><author><name sortKey="Losso, Marcelo" sort="Losso, Marcelo" uniqKey="Losso M" first="Marcelo" last="Losso">Marcelo Losso</name><affiliation><nlm:affiliation>Hospital General de Agudos J M Ramos Mejia Fundación IBIS Coordinacion de Investigacion Clinica Academica en Latinoamerica.</nlm:affiliation></affiliation></author><author><name sortKey="Porteiro, Norma" sort="Porteiro, Norma" uniqKey="Porteiro N" first="Norma" last="Porteiro">Norma Porteiro</name><affiliation><nlm:affiliation>Fundación Infectologia de Atencion Ambulatoria, Buenos Aires, Argentina.</nlm:affiliation></affiliation></author><author><name sortKey="Sierra Madero, Juan" sort="Sierra Madero, Juan" uniqKey="Sierra Madero J" first="Juan" last="Sierra Madero">Juan Sierra Madero</name><affiliation><nlm:affiliation>Instituto Nacional de Ciencias Medicas y Nutriciòn Salvador Zubiran, Tlalpan, Mexico.</nlm:affiliation></affiliation></author><author><name sortKey="Belloso, Waldo" sort="Belloso, Waldo" uniqKey="Belloso W" first="Waldo" last="Belloso">Waldo Belloso</name><affiliation><nlm:affiliation>Fundación IBIS Coordinacion de Investigacion Clinica Academica en Latinoamerica Hospital Italiano de Buenos Aires, Argentina.</nlm:affiliation></affiliation></author><author><name sortKey="Tu, Elise" sort="Tu, Elise" uniqKey="Tu E" first="Elise" last="Tu">Elise Tu</name><affiliation><nlm:affiliation>The Kirby Institute, University of New South Wales, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Silk, David" sort="Silk, David" uniqKey="Silk D" first="David" last="Silk">David Silk</name><affiliation><nlm:affiliation>The Kirby Institute, University of New South Wales, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Kelleher, Anthony" sort="Kelleher, Anthony" uniqKey="Kelleher A" first="Anthony" last="Kelleher">Anthony Kelleher</name><affiliation><nlm:affiliation>The Kirby Institute, University of New South Wales, Sydney, Australia St Vincent's Hospital, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Harrigan, Richard" sort="Harrigan, Richard" uniqKey="Harrigan R" first="Richard" last="Harrigan">Richard Harrigan</name><affiliation><nlm:affiliation>British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Clark, Andrew" sort="Clark, Andrew" uniqKey="Clark A" first="Andrew" last="Clark">Andrew Clark</name><affiliation><nlm:affiliation>ViiV Healthcare Ltd, London, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Sugiura, Wataru" sort="Sugiura, Wataru" uniqKey="Sugiura W" first="Wataru" last="Sugiura">Wataru Sugiura</name><affiliation><nlm:affiliation>Nagoya Medical Centre, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Wolff, Marcelo" sort="Wolff, Marcelo" uniqKey="Wolff M" first="Marcelo" last="Wolff">Marcelo Wolff</name><affiliation><nlm:affiliation>Fundacion Arriaran, Santiago, Chile.</nlm:affiliation></affiliation></author><author><name sortKey="Gill, John" sort="Gill, John" uniqKey="Gill J" first="John" last="Gill">John Gill</name><affiliation><nlm:affiliation>Southern Alberta Clinic, Calgary, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Gatell, Jose" sort="Gatell, Jose" uniqKey="Gatell J" first="Jose" last="Gatell">Jose Gatell</name><affiliation><nlm:affiliation>Hospital Clinic de Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Fisher, Martin" sort="Fisher, Martin" uniqKey="Fisher M" first="Martin" last="Fisher">Martin Fisher</name><affiliation><nlm:affiliation>Brighton and Sussex University Hospitals National Health Service Trust, Brighton, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Clarke, Amanda" sort="Clarke, Amanda" uniqKey="Clarke A" first="Amanda" last="Clarke">Amanda Clarke</name><affiliation><nlm:affiliation>Brighton and Sussex University Hospitals National Health Service Trust, Brighton, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Ruxrungtham, Kiat" sort="Ruxrungtham, Kiat" uniqKey="Ruxrungtham K" first="Kiat" last="Ruxrungtham">Kiat Ruxrungtham</name><affiliation><nlm:affiliation>HIV Netherlands, Australia, Thailand Research Collaboration, Bangkok.</nlm:affiliation></affiliation></author><author><name sortKey="Prazuck, Thierry" sort="Prazuck, Thierry" uniqKey="Prazuck T" first="Thierry" last="Prazuck">Thierry Prazuck</name><affiliation><nlm:affiliation>Orleans Hospital (Centre Hospitalier Regional D'Orleans Orleans La Source), France.</nlm:affiliation></affiliation></author><author><name sortKey="Kaiser, Rolf" sort="Kaiser, Rolf" uniqKey="Kaiser R" first="Rolf" last="Kaiser">Rolf Kaiser</name><affiliation><nlm:affiliation>Institut für Virologie, Cologne, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Woolley, Ian" sort="Woolley, Ian" uniqKey="Woolley I" first="Ian" last="Woolley">Ian Woolley</name><affiliation><nlm:affiliation>Monash Medical Centre, Melbourne, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Arnaiz, Juan Alberto" sort="Arnaiz, Juan Alberto" uniqKey="Arnaiz J" first="Juan Alberto" last="Arnaiz">Juan Alberto Arnaiz</name><affiliation><nlm:affiliation>Fundacion Clinic Spain Clinical Trials Unit, Barcelona.</nlm:affiliation></affiliation></author><author><name sortKey="Cooper, David" sort="Cooper, David" uniqKey="Cooper D" first="David" last="Cooper">David Cooper</name><affiliation><nlm:affiliation>The Kirby Institute, University of New South Wales, Sydney, Australia St Vincent's Hospital, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Rockstroh, Jurgen K" sort="Rockstroh, Jurgen K" uniqKey="Rockstroh J" first="Jürgen K" last="Rockstroh">Jürgen K. Rockstroh</name><affiliation><nlm:affiliation>Department of Medicine I, University Hospital Bonn, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Mallon, Patrick" sort="Mallon, Patrick" uniqKey="Mallon P" first="Patrick" last="Mallon">Patrick Mallon</name><affiliation><nlm:affiliation>Mater Misericordiae University Hospital, Dublin, Ireland.</nlm:affiliation></affiliation></author><author><name sortKey="Emery, Sean" sort="Emery, Sean" uniqKey="Emery S" first="Sean" last="Emery">Sean Emery</name><affiliation><nlm:affiliation>The Kirby Institute, University of New South Wales, Sydney, Australia.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</title><idno type="eISSN">1537-6591</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Comorbidity</term><term>Cyclohexanes (therapeutic use)</term><term>Female</term><term>HIV Fusion Inhibitors (therapeutic use)</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (epidemiology)</term><term>HIV Infections (virology)</term><term>HIV Protease Inhibitors (therapeutic use)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Reverse Transcriptase Inhibitors (therapeutic use)</term><term>Ritonavir (therapeutic use)</term><term>Treatment Outcome</term><term>Triazoles (therapeutic use)</term><term>Viral Load</term><term>Virus Replication</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Cyclohexanes</term><term>HIV Fusion Inhibitors</term><term>HIV Protease Inhibitors</term><term>Reverse Transcriptase Inhibitors</term><term>Ritonavir</term><term>Triazoles</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Comorbidity</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term><term>Viral Load</term><term>Virus Replication</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Alternative combination antiretroviral therapies in virologically suppressed human immunodeficiency virus (HIV)-infected patients experiencing side effects and/or at ongoing risk of important comorbidities from current therapy are needed. Maraviroc (MVC), a chemokine receptor 5 antagonist, is a potential alternative component of therapy in those with R5-tropic virus.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27048747</PMID><DateCreated><Year>2016</Year><Month>06</Month><Day>11</Day></DateCreated><DateCompleted><Year>2017</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2017</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.</ArticleTitle><Pagination><MedlinePgn>122-32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciw207</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Alternative combination antiretroviral therapies in virologically suppressed human immunodeficiency virus (HIV)-infected patients experiencing side effects and/or at ongoing risk of important comorbidities from current therapy are needed. Maraviroc (MVC), a chemokine receptor 5 antagonist, is a potential alternative component of therapy in those with R5-tropic virus.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Maraviroc Switch Study is a randomized, multicenter, 96-week, open-label switch study in HIV type 1-infected adults with R5-tropic virus, virologically suppressed on a ritonavir-boosted protease inhibitor (PI/r) plus double nucleoside/nucleotide reverse transcriptase inhibitor (2 N(t)RTI) backbone. Participants were randomized 1:2:2 to current combination antiretroviral therapy (control), or replacing the protease inhibitor (MVC + 2 N(t)RTI arm) or the nucleoside reverse transcriptase inhibitor backbone (MVC + PI/r arm) with twice-daily MVC. The primary endpoint was the difference (switch minus control) in proportion with plasma viral load (VL) <200 copies/mL at 48 weeks. The switch arms were judged noninferior if the lower limit of the 95% confidence interval (CI) for the difference in the primary endpoint was < -12% in the intention-to-treat (ITT) population.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The ITT population comprised 395 participants (control, n = 82; MVC + 2 N(t)RTI, n = 156; MVC + PI/r, n = 157). Baseline characteristics were well matched. At week 48, noninferior rates of virological suppression were observed in those switching away from a PI/r (93.6% [95% CI, -9.0% to 2.2%] and 91.7% [95% CI, -9.6% to 3.8%] with VL <200 and <50 copies/mL, respectively) compared to the control arm (97.6% and 95.1% with VL <200 and <50 copies/mL, respectively). In contrast, MVC + PI/r did not meet noninferiority bounds and was significantly inferior (84.1% [95% CI, -19.8% to -5.8%] and 77.7% [95% CI, -24.9% to -8.4%] with VL <200 and <50 copies/mL, respectively) to the control arm in the ITT analysis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data support MVC as a switch option for ritonavir-boosted PIs when partnered with a 2-N(t)RTI backbone, but not as part of N(t)RTI-sparing regimens comprising MVC with PI/r.</AbstractText><AbstractText Label="CLINICAL TRIALS REGISTRATION" NlmCategory="BACKGROUND">NCT01384682.</AbstractText><CopyrightInformation>© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pett</LastName><ForeName>Sarah Lilian</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, Australia Medical Research Council Clinical Trials Unit, Institute of Clinical Trials and Methodology Clinical Research Group, Infection and Population Health, University College London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amin</LastName><ForeName>Janaki</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horban</LastName><ForeName>Andrejz</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Wojewodzki Szpital Zakazny Centrum Diagnostyki i Terapii AIDS, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrade-Villanueva</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hospital Civil de Guadalajara "Fray Antonio Alcalde," Jalisco, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Losso</LastName><ForeName>Marcelo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hospital General de Agudos J M Ramos Mejia Fundación IBIS Coordinacion de Investigacion Clinica Academica en Latinoamerica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porteiro</LastName><ForeName>Norma</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Fundación Infectologia de Atencion Ambulatoria, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sierra Madero</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Ciencias Medicas y Nutriciòn Salvador Zubiran, Tlalpan, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belloso</LastName><ForeName>Waldo</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Fundación IBIS Coordinacion de Investigacion Clinica Academica en Latinoamerica Hospital Italiano de Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tu</LastName><ForeName>Elise</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silk</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelleher</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, Australia St Vincent's Hospital, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrigan</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ViiV Healthcare Ltd, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugiura</LastName><ForeName>Wataru</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Nagoya Medical Centre, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolff</LastName><ForeName>Marcelo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fundacion Arriaran, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Southern Alberta Clinic, Calgary, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gatell</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hospital Clinic de Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fisher</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Brighton and Sussex University Hospitals National Health Service Trust, Brighton, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarke</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Brighton and Sussex University Hospitals National Health Service Trust, Brighton, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruxrungtham</LastName><ForeName>Kiat</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>HIV Netherlands, Australia, Thailand Research Collaboration, Bangkok.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prazuck</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Orleans Hospital (Centre Hospitalier Regional D'Orleans Orleans La Source), France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaiser</LastName><ForeName>Rolf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institut für Virologie, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woolley</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Monash Medical Centre, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnaiz</LastName><ForeName>Juan Alberto</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Fundacion Clinic Spain Clinical Trials Unit, Barcelona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, Australia St Vincent's Hospital, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rockstroh</LastName><ForeName>Jürgen K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Medicine I, University Hospital Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallon</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Mater Misericordiae University Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emery</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Maraviroc Switch (MARCH) Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01384682</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>04</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003510">Cyclohexanes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D023581">HIV Fusion Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017320">HIV Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018894">Reverse Transcriptase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014230">Triazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>MD6P741W8A</RegistryNumber><NameOfSubstance UI="C502411">maraviroc</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003510" MajorTopicYN="N">Cyclohexanes</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023581" MajorTopicYN="N">HIV Fusion Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017320" MajorTopicYN="N">HIV Protease Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018894" MajorTopicYN="N">Reverse Transcriptase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014230" MajorTopicYN="N">Triazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HIV-1</Keyword><Keyword MajorTopicYN="N">antiretroviral</Keyword><Keyword MajorTopicYN="N">comorbidity</Keyword><Keyword MajorTopicYN="N">maraviroc</Keyword><Keyword MajorTopicYN="N">switch</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Kelleher</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Merlin</LastName><ForeName>Kate</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yeung</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fsadni</LastName><ForeName>Bertha</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marks</LastName><ForeName>Kat</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Kazuo</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rismanto</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salomon</LastName><ForeName>Horacio</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rubio</LastName><ForeName>Andrea E</ForeName><Initials>AE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chibo</LastName><ForeName>Doris</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Birch</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harrigan</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swenson</LastName><ForeName>Luke</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chan</LastName><ForeName>Dennison</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berg</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obermeier</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaiser</LastName><ForeName>Rolf</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schuelter</LastName><ForeName>Eugen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sierra Aragon</LastName><ForeName>Saleta</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luebke</LastName><ForeName>Nadine</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coughlan</LastName><ForeName>Suzie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dean</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sugiura</LastName><ForeName>Wataru</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iwatani</LastName><ForeName>Yasumasa</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reyes Teran</LastName><ForeName>Gustavo</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Avila</LastName><ForeName>Santiago</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruxrungtham</LastName><ForeName>Kiat</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sirivichayakul</LastName><ForeName>Sunee</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Naphassanant</LastName><ForeName>May</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ubolyam</LastName><ForeName>Sasiwimol</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Steve</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Land</LastName><ForeName>Sally</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walker</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haubrich</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeJesus</LastName><ForeName>Edwin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Emery</LastName><ForeName>Sean</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pett</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tu</LastName><ForeName>Elise</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silk</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berthon-Jones</LastName><ForeName>Nisha</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amin</LastName><ForeName>Janaki</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Espinosa</LastName><ForeName>Natalie</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Courtney-Vega</LastName><ForeName>Kymme</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Absar</LastName><ForeName>Noorul</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haskelberg</LastName><ForeName>Hila</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robson</LastName><ForeName>Rose</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donaldson</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Losso</LastName><ForeName>Marcelo</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belloso</LastName><ForeName>Waldo</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guelman</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gambardella</LastName><ForeName>Luciana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valdovinos</LastName><ForeName>Mariana</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gatell</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnaiz</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beleta</LastName><ForeName>Helena</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramos</LastName><ForeName>Nuria</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Targa</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rockstroh</LastName><ForeName>Jurgen</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Späth</LastName><ForeName>Brigitta</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boesecke</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Engelhardt</LastName><ForeName>Angelika</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fisher</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perry</LastName><ForeName>Nicky</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clarke</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gill</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckthold</LastName><ForeName>Brenda</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drummond</LastName><ForeName>Fraser</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lefevre</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corr</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grant</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lupo</LastName><ForeName>Sergio</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peroni</LastName><ForeName>Luciana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Italiano</LastName><ForeName>Hospital</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanchez</LastName><ForeName>Marisa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Paz Sierra</LastName><ForeName>Mariana</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mejia</LastName><ForeName>Ramos</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Losso</LastName><ForeName>Marcelo</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Viloria</LastName><ForeName>Guillermo</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parlante</LastName><ForeName>Angel</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bissio</LastName><ForeName>Emiliano</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luchetti</LastName><ForeName>Pablo</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Warley</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vieni</LastName><ForeName>Ines</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porteiro</LastName><ForeName>Norma</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vilas</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zarate</LastName><ForeName>Abel</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mayer</LastName><ForeName>Gabriela</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elliot</LastName><ForeName>Julian</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hagenauer</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kelley</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rowling</LastName><ForeName>Diane</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gibson</LastName><ForeName>Abby</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Latch</LastName><ForeName>Ngaire</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tabrett</LastName><ForeName>Chantal</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Warzywoda</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cooper</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pett</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacRae</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinclair</LastName><ForeName>Brett</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinn</LastName><ForeName>Kate</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bloch</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franic</LastName><ForeName>Teo</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vincent</LastName><ForeName>Trina</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stewart</LastName><ForeName>Natasha</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jayewardene</LastName><ForeName>Avindra</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dwyer</LastName><ForeName>Dominic</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kok</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Assam</LastName><ForeName>Delene</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>Janette</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>King</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Orth</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Youds</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sowden</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnston</LastName><ForeName>Colleen</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murray</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hehir</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wadham</LastName><ForeName>Samantha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garsia</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turnham</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Madden</LastName><ForeName>Tracey</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woolley</LastName><ForeName>Ian</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gillies</LastName><ForeName>Ainsley</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bryant</LastName><ForeName>Mellissa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gill</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckthold</LastName><ForeName>Brenda</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walmsley</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chan</LastName><ForeName>Warmond</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>LeBlanc</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lanteigne</LastName><ForeName>Francois</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mouawad</LastName><ForeName>Rima</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rahal</LastName><ForeName>Ines</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guber</LastName><ForeName>Sergio</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ozturk</LastName><ForeName>Sefika</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Graham</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Halpenny</LastName><ForeName>Roberta</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reko</LastName><ForeName>Tatjana</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robinette Hills</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolff</LastName><ForeName>Marcelo</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prazuck</LastName><ForeName>Thierry</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laurent Hocqueloux</LastName><ForeName>Francois</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolfgang</LastName><ForeName>Johann</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stephan</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ebeling</LastName><ForeName>Franziska</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rockstroh</LastName><ForeName>Juergen</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boesecke</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spath</LastName><ForeName>Brigitta</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Engelhardt</LastName><ForeName>Angelika</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ole Jensen</LastName><ForeName>Bjorn-Erik</ForeName><Initials>BE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feind</LastName><ForeName>Cecilie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meyer-Olson</LastName><ForeName>Dirk</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stoll</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoeper</LastName><ForeName>Kirsten</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beider</LastName><ForeName>Renata</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faetkenheur</LastName><ForeName>Gerd</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas Baumgarten</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baumgarten</LastName><ForeName>Axel</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ingiliz</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wienbreyer</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Behrendt</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nienkarken</LastName><ForeName>Tanja</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stein</LastName><ForeName>Jessen</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jessen</LastName><ForeName>Heiko</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zedlack</LastName><ForeName>Carmen</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mallon</LastName><ForeName>Paddy</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simelane</LastName><ForeName>Sibongile</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Assmann</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghavami-Kia</LastName><ForeName>Bijan</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sugiura</LastName><ForeName>Wataru</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Imahashi</LastName><ForeName>Mayumi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tanabe</LastName><ForeName>Kazue</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yokomaku</LastName><ForeName>Yoshiyuki</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Imamura</LastName><ForeName>Junji</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andrade-Villanueva</LastName><ForeName>Jaime</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montes de Oca</LastName><ForeName>Melva</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Lucero</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ponce</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mendoza</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sierra-Madero</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanchez Hernandez</LastName><ForeName>Jesus Eduardo</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jaime Ruiz Ballesteros</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Del Moral Ponce</LastName><ForeName>Sergio</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mosqueda</LastName><ForeName>Luis</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horban</LastName><ForeName>Andrzej</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ignatowska</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bakowska</LastName><ForeName>Elzbieta</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pulik</LastName><ForeName>Piotr</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanz-Moreno</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paredes</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Puig</LastName><ForeName>Jordi</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Domingo</LastName><ForeName>Pere</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gutierrez</LastName><ForeName>Mar</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gatell</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>González-Cordón</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Callau</LastName><ForeName>Pili</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez Aldeguer</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cuellar Tovar</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leal Noval</LastName><ForeName>Manuel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rivas</LastName><ForeName>Inmaculada</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delgado-Fernandez</LastName><ForeName>Marcial</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramon Arribas</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miguel Castro</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruxrungtham</LastName><ForeName>Kiat</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Avihingsanon</LastName><ForeName>Anchalee</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maek-A-Nantawat</LastName><ForeName>Wirach</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Intasan</LastName><ForeName>Jintana</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charoenporn</LastName><ForeName>Walairat</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cuprasitrut</LastName><ForeName>Thidarat</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jaisomkom</LastName><ForeName>Pachuen</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pruksakaew</LastName><ForeName>Kanchana</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winston</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mullaney</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fisher</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clarke</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barbour</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perry</LastName><ForeName>Nicky</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richardson</LastName><ForeName>Celia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murray</LastName><ForeName>Tammy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leen</LastName><ForeName>Clifford</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>Shelia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Satyajit</LastName><ForeName>Das</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sandhu</LastName><ForeName>Rumun</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tucker</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>03</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27048747</ArticleId><ArticleId IdType="pii">ciw207</ArticleId><ArticleId IdType="doi">10.1093/cid/ciw207</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C06 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001C06 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27048747
|texte= Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27048747" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |